Bosutinib
About
Therapy type: Targeted therapy
Therapy strategy: BCR-ABL inhibition
Mappings
NCI Thesaurus: Bosutinib (ncit:C60809)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | BCR::ABL1 | Chronic Myelogenous Leukemia | Bosutinib | |
| Sensitivity (+) | BCR::ABL1 | Chronic Myelogenous Leukemia | Bosutinib | |
| Sensitivity (+) | BCR::ABL1 | Chronic Myelogenous Leukemia | Bosutinib | |
| Sensitivity (+) | BCR::ABL1 | Chronic Myelogenous Leukemia | Bosutinib | |
| Sensitivity (+) | BCR::ABL1 | Chronic Myelogenous Leukemia | Bosutinib | |
| Sensitivity (+) | BCR::ABL1 | Chronic Myelogenous Leukemia | Bosutinib |